Octagon Capital Advisors »

Regulus Therapeutics shares owned by Octagon Capital Advisors

Quarter-by-quarter ownership of Regulus Therapeutics (RGLS) shares owned by Octagon Capital Advisors from 13F filings

Historical chart of Octagon Capital Advisors investment in Regulus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Regulus Therapeutics held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Regulus Therapeutics by Octagon Capital Advisors

Quarter filed Position value Share count Share price at filing
2024-06-30 $7.6M 4.3M 1.79

More positions owned by Octagon Capital Advisors

Apellis Pharmaceuticals Call Option (APLS)
Insmed Com Par $.01 Call Option (INSM)
Dianthus Therapeutics (DNTH)
Structure Therapeutics Sponsored Ads (GPCR)
Dyne Therapeutics (DYN)
Arrivent Biopharma (AVBP)
Verona Pharma Sponsored Ads (VRNA)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Bridgebio Pharma (BBIO)
Ocular Therapeutix (OCUL)
Perspective Therapeutics Com New (CATX)
Mind Medicine Mindmed Com New (MNMD)
Praxis Precision Medicines I Com New (PRAX)
Taysha Gene Therapies Com Shs (TSHA)

View all positions for Octagon Capital Advisors

Top funds holding Regulus Therapeutics

Federated Investors
RA Capital Management
Octagon Capital Advisors
Vanguard Group
BlackRock
Deep Track Capital
Opaleye Management
Geode Capital Management
Millennium Management
State Street Corporation
Woodline Partners
Alyeska Investment Group
DAFNA Capital Management
CVI Holdings
Victory Capital Management

View all funds holding Regulus Therapeutics